ANABV — AnaptysBio Share News
0.000.00%
Last trade - 00:00- $1.94bn
- $1.91bn
- $234.60m
AnaptysBio Inc expected to post a loss of $1.59 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Apollo, Booking Holdings, Portillos
Brief: AnaptysBio Q3 Net Income USD -32.851 Million
U.S. STOCKS ON THE MOVE-Zimmer Biomet, Shake Shack, Microsoft
U.S. STOCKS ON THE MOVE-XPO, Blueprint Medicines, AbbVie
AnaptysBio plunges as Eli Lilly drops co's arthritis drug from pipeline
U.S. RESEARCH ROUNDUP-Amgen, Atkore, Moneylion
U.S. RESEARCH ROUNDUP- Actinium Pharmaceuticals, Albemarle, ArcBest
AnaptysBio Inc reports results for the quarter ended in June - Earnings Summary
Brief: AnaptysBio Q2 Net Income USD -46.66 Million
AnaptysBio Inc expected to post a loss of 89 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Anaptysbio, Blackstone, Netflix
U.S. RESEARCH ROUNDUP- Altus Power, Jack in the Box, Home Depot
U.S. RESEARCH ROUNDUP- Altus Power, Jack in the Box, Home Depot
AnaptysBio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis
Brief: Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties
Brief: AnaptysBio Q1 Net Income USD -43.936 Million
AnaptysBio Inc expected to post a loss of $1.57 a share - Earnings Preview